Thiago Gagliano Juca D Oliveira, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 18 | 2023 | 2472 | 3.540 |
Why?
|
| Androgens | 6 | 2023 | 1283 | 1.660 |
Why?
|
| Androgen Antagonists | 4 | 2023 | 1408 | 1.440 |
Why?
|
| Hormone Replacement Therapy | 5 | 2023 | 751 | 1.350 |
Why?
|
| Hypogonadism | 5 | 2023 | 798 | 1.240 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 457 | 0.720 |
Why?
|
| Prilocaine | 2 | 2016 | 21 | 0.640 |
Why?
|
| Anesthetics, Local | 2 | 2016 | 997 | 0.630 |
Why?
|
| Agrin | 1 | 2017 | 75 | 0.580 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2017 | 74 | 0.560 |
Why?
|
| Leuprolide | 1 | 2018 | 312 | 0.550 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 11103 | 0.550 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 295 | 0.540 |
Why?
|
| Molluscum Contagiosum | 1 | 2016 | 15 | 0.540 |
Why?
|
| Tinea Versicolor | 1 | 2015 | 9 | 0.520 |
Why?
|
| Naproxen | 1 | 2016 | 100 | 0.520 |
Why?
|
| Medical Records | 1 | 2021 | 1409 | 0.520 |
Why?
|
| Pain Perception | 1 | 2017 | 196 | 0.520 |
Why?
|
| Ketoconazole | 1 | 2015 | 97 | 0.500 |
Why?
|
| Lidocaine | 2 | 2016 | 538 | 0.500 |
Why?
|
| Cryotherapy | 1 | 2016 | 159 | 0.490 |
Why?
|
| Documentation | 1 | 2021 | 898 | 0.480 |
Why?
|
| Stomach Diseases | 1 | 2016 | 134 | 0.480 |
Why?
|
| Erythropoiesis | 1 | 2018 | 683 | 0.470 |
Why?
|
| Blood Platelets | 3 | 2020 | 2477 | 0.470 |
Why?
|
| Drug Tolerance | 1 | 2016 | 367 | 0.460 |
Why?
|
| Nanocapsules | 1 | 2015 | 94 | 0.460 |
Why?
|
| Terminology as Topic | 1 | 2021 | 1528 | 0.460 |
Why?
|
| Erythropoietin | 1 | 2018 | 719 | 0.450 |
Why?
|
| Mobility Limitation | 1 | 2017 | 408 | 0.440 |
Why?
|
| Alanine | 1 | 2016 | 608 | 0.440 |
Why?
|
| Quinolones | 1 | 2016 | 378 | 0.420 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 1520 | 0.410 |
Why?
|
| Sarcopenia | 1 | 2017 | 370 | 0.410 |
Why?
|
| Exercise Test | 1 | 2020 | 2165 | 0.400 |
Why?
|
| Thromboembolism | 1 | 2018 | 993 | 0.380 |
Why?
|
| Administration, Cutaneous | 3 | 2020 | 713 | 0.380 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 510 | 0.370 |
Why?
|
| Spleen | 1 | 2017 | 2290 | 0.370 |
Why?
|
| Dyslipidemias | 1 | 2018 | 870 | 0.370 |
Why?
|
| Monocytes | 1 | 2020 | 2570 | 0.360 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 1277 | 0.350 |
Why?
|
| Double-Blind Method | 9 | 2021 | 12341 | 0.340 |
Why?
|
| Glucose | 2 | 2019 | 4341 | 0.340 |
Why?
|
| Imidazoles | 1 | 2015 | 1173 | 0.330 |
Why?
|
| Neutrophils | 1 | 2020 | 3763 | 0.290 |
Why?
|
| Insulin Resistance | 2 | 2018 | 3951 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 10213 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2270 | 0.260 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5103 | 0.240 |
Why?
|
| Lipoproteins | 2 | 2019 | 878 | 0.230 |
Why?
|
| Cytokines | 1 | 2018 | 7386 | 0.220 |
Why?
|
| Dinoprostone | 2 | 2016 | 597 | 0.210 |
Why?
|
| Gastric Mucosa | 2 | 2016 | 603 | 0.210 |
Why?
|
| Male | 25 | 2023 | 360675 | 0.210 |
Why?
|
| Aging | 3 | 2023 | 8701 | 0.200 |
Why?
|
| Kidney | 1 | 2017 | 7034 | 0.190 |
Why?
|
| Liver | 1 | 2017 | 7513 | 0.190 |
Why?
|
| Sex Reassignment Procedures | 1 | 2022 | 70 | 0.190 |
Why?
|
| Myostatin | 1 | 2022 | 129 | 0.180 |
Why?
|
| Pain | 1 | 2016 | 5070 | 0.180 |
Why?
|
| Gels | 1 | 2020 | 420 | 0.160 |
Why?
|
| Testis | 1 | 2022 | 781 | 0.160 |
Why?
|
| Humans | 28 | 2023 | 761098 | 0.160 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 157 | 0.150 |
Why?
|
| Body Composition | 2 | 2018 | 2427 | 0.150 |
Why?
|
| Middle Aged | 15 | 2023 | 220835 | 0.150 |
Why?
|
| Depression | 1 | 2017 | 8130 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 11475 | 0.140 |
Why?
|
| Cardiac Output | 1 | 2019 | 831 | 0.140 |
Why?
|
| Endothelium | 1 | 2019 | 763 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 15513 | 0.130 |
Why?
|
| Prolactin | 1 | 2018 | 625 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2019 | 932 | 0.130 |
Why?
|
| Methotrexate | 1 | 2023 | 1717 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 612 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2021 | 6390 | 0.130 |
Why?
|
| Luteinizing Hormone | 1 | 2018 | 820 | 0.130 |
Why?
|
| Dietary Proteins | 1 | 2021 | 951 | 0.130 |
Why?
|
| Ferritins | 1 | 2018 | 597 | 0.130 |
Why?
|
| Physical Fitness | 1 | 2020 | 742 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2022 | 1186 | 0.130 |
Why?
|
| Stroke | 1 | 2018 | 9720 | 0.130 |
Why?
|
| Young Adult | 9 | 2018 | 59199 | 0.130 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1178 | 0.120 |
Why?
|
| Piracetam | 1 | 2015 | 88 | 0.120 |
Why?
|
| Pain Measurement | 2 | 2016 | 3548 | 0.120 |
Why?
|
| Aged | 9 | 2023 | 169266 | 0.120 |
Why?
|
| Social Stigma | 1 | 2021 | 770 | 0.120 |
Why?
|
| Propylthiouracil | 1 | 2014 | 68 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 1381 | 0.120 |
Why?
|
| Carnitine | 1 | 2015 | 252 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 274 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 838 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 1535 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 12145 | 0.110 |
Why?
|
| Insulin | 2 | 2018 | 6588 | 0.110 |
Why?
|
| Anthropometry | 1 | 2018 | 1338 | 0.110 |
Why?
|
| Electrocardiography | 2 | 2017 | 6385 | 0.110 |
Why?
|
| Pain Threshold | 1 | 2017 | 603 | 0.110 |
Why?
|
| Administration, Topical | 1 | 2015 | 703 | 0.110 |
Why?
|
| Muscle Strength | 1 | 2017 | 624 | 0.110 |
Why?
|
| Adult | 12 | 2022 | 221083 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 1409 | 0.100 |
Why?
|
| Organ Size | 1 | 2017 | 2253 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 2420 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2020 | 64670 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1893 | 0.090 |
Why?
|
| Body Weight | 1 | 2021 | 4618 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2015 | 753 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 1669 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2016 | 2048 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1885 | 0.080 |
Why?
|
| Obesity | 2 | 2022 | 12937 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2018 | 54419 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 956 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2019 | 3111 | 0.070 |
Why?
|
| Lipids | 1 | 2018 | 3330 | 0.070 |
Why?
|
| Adolescent | 7 | 2018 | 88271 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10755 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6305 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 20120 | 0.060 |
Why?
|
| Aspirin | 1 | 2016 | 3128 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2015 | 265 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 2746 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15845 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2019 | 3405 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 58946 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4947 | 0.050 |
Why?
|
| Disease Progression | 1 | 2019 | 13506 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14607 | 0.050 |
Why?
|
| Growth Differentiation Factors | 1 | 2022 | 100 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 3808 | 0.050 |
Why?
|
| Self Administration | 1 | 2022 | 387 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2022 | 555 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2022 | 672 | 0.040 |
Why?
|
| Female | 8 | 2022 | 392458 | 0.040 |
Why?
|
| Animals | 2 | 2022 | 168083 | 0.040 |
Why?
|
| Reproduction | 1 | 2023 | 646 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 982 | 0.040 |
Why?
|
| Quality of Life | 1 | 2017 | 13362 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 41486 | 0.030 |
Why?
|
| Tablets | 1 | 2015 | 148 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 1738 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 389 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 273 | 0.030 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 134 | 0.030 |
Why?
|
| Pelvis | 1 | 2018 | 734 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 42217 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 36418 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 74219 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5249 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 2081 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 4849 | 0.020 |
Why?
|
| Child | 1 | 2016 | 80134 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 4014 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3367 | 0.010 |
Why?
|
| Linear Models | 1 | 2014 | 5869 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14676 | 0.010 |
Why?
|